Oric Pharmaceuticals Inc. (ORIC): Price and Financial Metrics

Oric Pharmaceuticals Inc. (ORIC): $3.20

-0.04 (-1.23%)

POWR Rating

Component Grades













Add ORIC to Watchlist
Sign Up

Industry: Biotech



in industry

ORIC Stock Price Chart Interactive Chart >

Price chart for ORIC

ORIC Price/Volume Stats

Current price $3.20 52-week high $21.18
Prev. close $3.24 52-week low $2.62
Day low $3.04 Volume 136,800
Day high $3.31 Avg. volume 383,469
50-day MA $3.87 Dividend yield N/A
200-day MA $6.23 Market Cap 126.65M

Oric Pharmaceuticals Inc. (ORIC) Company Bio

Oric Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Latest News Stream

Event/Time News Detail
Loading, please wait...

ORIC Latest Social Stream

Loading social stream, please wait...

View Full ORIC Social Stream

Latest ORIC News From Around the Web

Below are the latest news stories about ORIC PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ORIC as an investment opportunity.

Merck's (MRK) Keytruda Gets Four New Approvals in Japan

The Ministry of Health, Labour and Welfare approves Merck's (MRK) anti-PD-1 therapy, Keytruda, for four new cancer indications in Japan.

Yahoo | September 28, 2022

Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study

Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.

Yahoo | September 22, 2022

Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod

The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.

Yahoo | September 21, 2022

Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal

Horizon's (HZNP) phase II study on dazodalibep for treating patients with Sjogren's syndrome meets the primary endpoint.

Yahoo | September 13, 2022

Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review

The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.

Yahoo | September 13, 2022

Read More 'ORIC' Stories Here

ORIC Price Returns

1-mo -7.25%
3-mo -27.27%
6-mo -54.74%
1-year -84.24%
3-year N/A
5-year N/A
YTD -78.23%
2021 -56.57%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6136 seconds.